Select Publications

Ahn JH Sr et al. Phase II study of combination chemotherapy of capecitabine and vinorelbine in metastatic breast cancer with previous exposure to anthracycline and taxane: Preliminary results. Proc ASCO 2002;Abstract 2030.

Bajetta E et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005 Feb 14;[Epub ahead of print]. Abstract

Blum JL et al. A Phase II trial of combination therapy with capecitabine (C) and weekly paclitaxel (P) for metastatic breast cancer (MBC): Preliminary results in taxane-naive patients. Poster. San Antonio Breast Cancer Symposium 2004;Abstract 5053.

Buzdar AU et al. Significantly higher pathological complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23(16);[Epub ahead of print]. Abstract

Domenech G et al. Vinorelbine/capecitabine (VINOCAP) combination remission induction therapy for metastatic breast cancer (MBC). Proc ASCO 2001;Abstract 1939.

Estevez LG et al. Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Proc ASCO 2004;Abstract 748.

Geyer CE Jr et al. Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus trastuzumab in patients (Pts) with operable, nodepositive (N+), HER-2 overexpressing breast cancer (HER2+BC). San Antonio Breast Cancer Symposium 2003;Abstract 23.

Ghosn M et al. Final results of a phase II study of vinorelbine in combination with capecitabine as first line chemotherapy for metastatic breast cancer (MBC). Proc ASCO 2003;Abstract 270.

Gligorov J et al. Capecitabine and oral vinorelbine in metastatic breast cancer: Preliminary experience. Proc ASCO 2003;Abstract 351.

Gradishar WJ et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study. J Clin Oncol 2004;22(12):2321-7. Abstract

Hess DD et al. Phase I-II trial of capecitabine and vinorelbine in elderly patients (pts: > 65y) with metastatic breast cancer (MBC): SAKK 25/99 for the Swiss Group of Clinical Cancer Research, Berne, Switzerland. Proc ASCO 2002;Abstract 2915.

Hurley J et al. Platinum salts and docetaxel as primary therapy of locally advanced and inflammatory breast cancer: The final report of three sequential studies. San Antonio Breast Cancer Symposium 2003;Abstract 238.

O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract

Stuart N et al. Vinorelbine and capecitabine (VX) for advanced breast cancer — A phase II study showing good activity and potential for further development. Proc ASCO 2003;Abstract 183.

Xu B et al. Capecitabine (X) combined with vinorelbine (V) in Chinese patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2004;Abstract 741.